GYRE Stock Analysis: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$6.48
0.35 (5.71%)
▲
5d:
+11.34%
30d:
+6.93%
90d:
-6.63%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GYRE shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: GYRE shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $6.48, which is considered extended relative to its 30-day fair value range of $5.82 to $6.25. From a valuation perspective, the stock is trading at a discount (Forward PE: -56.4) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is in a strong downtrend. Immediate support is located at $5.74, while resistance sits at $6.69. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+188.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GYRE is in a strong downtrend. Immediate support is located at $5.74, while resistance sits at $6.69. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+188.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.82 -
$6.25
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.7%)
- BULLISH: Trading 188.1% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$5.82 -
$6.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.74
Resistance Level
$6.69
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-56.35
Wall Street Target
$18.67
(+188.1%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
166.2%
Profit Margin
-5.4%
PE vs Historical
-56.4 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: June 25, 2026 3:19 AM ET
Data refreshes hourly during market hours. Next update: 4:19 AM
Data refreshes hourly during market hours. Next update: 4:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 61 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
